+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Therapy Starting Materials Market Size, Share & Trends Analysis Report by Product (Viral Vectors, Plasmid DNA, Cell Lines), Development Stage, Application, End Use, Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 6085833
Description Jump to:
The Gene Therapy Starting Materials Market was valued at USD 1.90 Billion in 2024, and is projected to reach USD 5.40 Billion by 2030, rising at a CAGR of 19.24%. This growth is driven by increasing demand for high-quality raw materials to support the expanding pipeline of gene therapies targeting rare and genetic disorders, cancer, and other complex conditions. As more therapies advance through clinical trials and gain regulatory approvals, the need for scalable, GMP-compliant plasmids, viral vectors, and other key inputs continues to rise.

Furthermore, technological advancements, growing R&D investments, and supportive regulatory frameworks are further accelerating the market. In addition, partnerships between biotech firms and manufacturers are enhancing production capabilities and ensuring a consistent supply chain, positioning the gene therapy starting materials industry for strong and sustained growth through the forecast period.

The COVID-19 pandemic further accelerated the demand for gene therapy starting materials by highlighting the need for rapid therapeutic development and scalable manufacturing. It spurred investments in advanced bioproduction infrastructure and increased focus on genetic platforms, driving growth in plasmid DNA, viral vectors, and other critical components used in both vaccine and gene therapy development.

In addition, the expanding pipeline of gene therapies has further fueled market growth. As more therapies advance into clinical trials and receive regulatory approvals, the demand for high-quality starting materials such as plasmid DNA and viral vectors continues to rise. This has prompted increased investments in manufacturing capacity, advanced technologies, and strategic partnerships, enabling efficient scale-up and supply to meet the evolving needs of gene therapy developers worldwide.

However, strict regulatory requirements for safety, quality, and compliance can delay the development and approval of gene therapy products. While essential for ensuring patient safety, these regulations often involve complex documentation, extensive testing, and prolonged review timelines. This can slow market entry, increase operational costs, and create barriers for smaller companies with limited regulatory expertise. As the industry evolves, navigating these requirements remains a critical challenge for stakeholders in the gene therapy starting materials market.

Gene Therapy Starting Materials Market Report Highlights

  • The viral vectors segment led the market with the largest revenue share of 42.91% in 2024, owing to their high efficiency in gene delivery and widespread use in approved gene therapies. However, the plasmid DNA segment is expected to grow at the fastest CAGR of 20.13% over the forecast period.
  • Based on development stage, the clinical therapeutics segment accounted for the largest market share in 2024, driven by the growing number of gene therapy candidates advancing through clinical trials. On the other hand, the pre-clinical therapeutics segment is expected to witness at the fastest CAGR over the forecast period.
  • Based on application, the oncology segment accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, attributed to the rising prevalence of cancer, strong clinical pipeline, and increasing adoption of gene therapies targeting various tumor types. However, the genetic disease segment is projected to grow at a significant CAGR over the forecast period.
  • Based on end use, the biopharmaceutical and pharmaceutical companies segment accounted for the largest market revenue share in 2024, driven by increased investment in gene therapy R&D, in-house manufacturing capabilities, and strategic partnerships to accelerate therapy development. On the other hand, the CROs & CMOs segment is expected to register at the fastest CAGR during the projected period.
  • North America dominated the market with the largest revenue share in 2024 due to strong R&D investment, advanced manufacturing capabilities, and a high concentration of industry leaders. The Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Development Stage
1.2.3. Application
1.2.4. End-use
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Gene Therapy Starting Materials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Prevalence of Genetic and Rare Diseases
3.2.1.2. Expanding Pipeline of Gene Therapies
3.2.2. Market restraint analysis
3.2.2.1. Strict Regulatory Requirements
3.3. Gene Therapy Starting Materials Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Gene Therapy Starting Materials Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. Global Gene Therapy Starting Materials Market Product Movement Analysis
4.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Viral Vectors
4.4.1. Viral Vectors Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
4.4.2. Adenovirus
4.4.2.1. Adenovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.4.3. Retrovirus
4.4.3.1. Retrovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.4.4. Adeno-Associated Virus (AAV)
4.4.4.1. Adeno-Associated Virus (AAV) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.4.5. Lentivirus
4.4.5.1. Lentivirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Plasmid DNA
4.5.1. Plasmid DNA Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
4.6. Cell Lines
4.6.1. Cell Lines Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
Chapter 5. Gene Therapy Starting Materials Market: Development Stage Estimates & Trend Analysis
5.1. Development Stage Segment Dashboard
5.2. Global Gene Therapy Starting Materials Market Development Stage Movement Analysis
5.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Pre-clinical Therapeutics
5.4.1. Pre-clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
5.5. Clinical Therapeutics
5.5.1. Clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
5.6. Marketed Therapeutics
5.6.1. Marketed Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
Chapter 6. Gene Therapy Starting Materials Market: Application Estimates & Trend Analysis
6.1. Application Segment Dashboard
6.2. Global Gene Therapy Starting Materials Market Application Movement Analysis
6.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
6.5. Infectious Disease
6.5.1. Infectious Disease Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
6.6. Genetic Disease
6.6.1. Genetic Disease Market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
Chapter 7. Gene Therapy Starting Materials Market: End Use Estimates & Trend Analysis
7.1. End Use Segment Dashboard
7.2. Global Gene Therapy Starting Materials Market End Use Movement Analysis
7.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Biopharmaceutical & Pharmaceutical Companies
7.4.1. Biopharmaceutical & Pharmaceutical Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
7.5. CROs & CMOs
7.5.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
7.6. Other
7.6.1. Other Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
Chapter 8. Gene Therapy Starting Materials Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Company Market Position Analysis, 2024
9.3. Strategy Mapping
9.4. Participants Overview
9.4.1. Charles River Laboratories
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Thermo Fisher Scientific Inc.
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. GenScript
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Lonza
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Catalent
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Eurofins Scientific
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Danaher
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Merck KGaA
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Revvity, Inc.
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Sartorius AG
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America Gene Therapy Starting Materials Market, by Country, 2018-2030 (USD Million)
Table 3 North America Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 4 North America Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 5 North America Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 6 North America Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 7 US Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 8 US Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 9 US Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 10 US Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 11 Canada Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 12 Canada Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 13 Canada Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 14 Canada Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 15 Mexico Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 16 Mexico Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 17 Mexico Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 18 Mexico Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 19 Europe Gene Therapy Starting Materials Market, by Country, 2018-2030 (USD Million)
Table 20 Europe Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 21 Europe Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 22 Europe Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 23 Europe Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 24 UK Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 25 UK Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 26 UK Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 27 UK Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 28 Germany Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 29 Germany Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 30 Germany Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 31 Germany Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 32 Italy Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 33 Italy Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 34 Italy Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 35 Italy Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 36 France Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 37 France Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 38 France Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 39 France Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 40 Spain Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 41 Spain Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 42 Spain Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 43 Spain Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 44 Sweden Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 45 Sweden Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 46 Sweden Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 47 Sweden Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 48 Denmark Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 49 Denmark Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 50 Denmark Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 51 Denmark Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 52 Norway Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 53 Norway Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 54 Norway Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 55 Norway Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 56 Asia Pacific Gene Therapy Starting Materials Market, by Country, 2018-2030 (USD Million)
Table 57 Asia Pacific Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 58 Asia Pacific Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 59 Asia Pacific Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 60 Asia Pacific Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 61 China Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 62 China Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 63 China Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 64 China Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 65 Japan Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 66 Japan Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 67 Japan Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 68 Japan Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 69 India Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 70 India Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 71 India Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 72 India Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 73 South Korea Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 74 South Korea Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 75 South Korea Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 76 South Korea Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 77 Australia Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 78 Australia Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 79 Australia Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 80 Australia Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 81 Thailand Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 82 Thailand Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 83 Thailand Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 84 Thailand Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 85 Latin America Gene Therapy Starting Materials Market, by Country, 2018-2030 (USD Million)
Table 86 Latin America Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 87 Latin America Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 88 Latin America Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 89 Latin America Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 90 Brazil Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 91 Brazil Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 92 Brazil Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 93 Brazil Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 94 Argentina Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 95 Argentina Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 96 Argentina Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 97 Argentina Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 98 Middle East Africa Gene Therapy Starting Materials Market, by Country, 2018-2030 (USD Million)
Table 99 Middle East Africa Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 100 Middle East Africa Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 101 Middle East Africa Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 102 Middle East Africa Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 103 South Africa Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 104 South Africa Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 105 South Africa Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 106 South Africa Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 107 Saudi Arabia Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 108 Saudi Arabia Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 109 Saudi Arabia Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 110 Saudi Arabia Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 111 UAE Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 112 UAE Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 113 UAE Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 114 UAE Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
Table 115 Kuwait Gene Therapy Starting Materials Market, by Product, 2018-2030 (USD Million)
Table 116 Kuwait Gene Therapy Starting Materials Market, by Development Stage, 2018-2030 (USD Million)
Table 117 Kuwait Gene Therapy Starting Materials Market, by Application, 2018-2030 (USD Million)
Table 118 Kuwait Gene Therapy Starting Materials Market, by End-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market Research Process
Figure 2 Data Triangulation Techniques
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Market formulation & Validation
Figure 6 Gene Therapy Starting Materials Market: Market Outlook
Figure 7 Parent Market Outlook
Figure 8 Related/Ancillary Market Outlook
Figure 9 Gene Therapy Starting Materials Market Driver Impact
Figure 10 Gene Therapy Starting Materials Market Restraint Impact
Figure 11 Gene Therapy Starting Materials Market Strategic Initiatives Analysis
Figure 12 Gene Therapy Starting Materials Market: Product Movement Analysis
Figure 13 Gene Therapy Starting Materials Market: Product Outlook and Key Takeaways
Figure 14 Viral Vectors Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 15 Adenovirus Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 16 Retrovirus Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 17 Adeno-Associated Virus (AAV) Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 18 Lentivirus Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 19 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 20 Cell Lines Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 21 Plasmid DNA Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 22 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 23 Gene Therapy Starting Materials Market: Development Stage Movement Analysis
Figure 24 Gene Therapy Starting Materials Market: Development Stage Outlook and Key Takeaways
Figure 25 Pre-clinical Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 26 Clinical Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 27 Marketed Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 28 Gene Therapy Starting Materials Market: Application Movement Analysis
Figure 29 Gene Therapy Starting Materials Market: Application Outlook and Key Takeaways
Figure 30 Oncology Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 31 Infectious Disease Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 32 Cancer Diagnostics Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 33 Genetic Disease Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 34 Other Disease Diagnostic Applications Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 35 Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 Gene Therapy Starting Materials Market: End-Use Movement Analysis
Figure 37 Gene Therapy Starting Materials Market: End-Use Outlook and Key Takeaways
Figure 38 Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 39 CROs & CMOs Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 40 Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 Global Gene Therapy Starting Materials Market: Regional Movement Analysis
Figure 42 Global Gene Therapy Starting Materials Market: Regional Outlook and Key Takeaways
Figure 43 North America Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 44 US Country Dynamics
Figure 45 US Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 46 Canada Country Dynamics
Figure 47 Canada Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 48 Mexico Country Dynamics
Figure 49 Mexico Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 50 Europe Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 UK Country Dynamics
Figure 52 UK Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 53 Germany Country Dynamics
Figure 54 Germany Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 France Country Dynamics
Figure 56 France Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 Italy Country Dynamics
Figure 58 Italy Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 59 Spain Country Dynamics
Figure 60 Spain Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 61 Denmark Country Dynamics
Figure 62 Denmark Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 63 Sweden Country Dynamics
Figure 64 Sweden Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 65 Norway Country Dynamics
Figure 66 Norway Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 67 Asia Pacific Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 68 China Country Dynamics
Figure 69 China Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 70 Japan Country Dynamics
Figure 71 Japan Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 72 India Country Dynamics
Figure 73 India Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 74 Thailand Country Dynamics
Figure 75 Thailand Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 76 South Korea Country Dynamics
Figure 77 South Korea Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 78 Australia Country Dynamics
Figure 79 Australia Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 80 Latin America Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 81 Brazil Country Dynamics
Figure 82 Brazil Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 83 Argentina Country Dynamics
Figure 84 Argentina Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 85 Middle East and Africa Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 86 South Africa Country Dynamics
Figure 87 South Africa Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 88 Saudi Arabia Country Dynamics
Figure 89 Saudi Arabia Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 90 UAE Country Dynamics
Figure 91 UAE Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 92 Kuwait Country Dynamics
Figure 93 Kuwait Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 94 Market Position of Key Market Players

Companies Mentioned

The companies profiled in this Gene Therapy Starting Materials market report include:
  • Charles River Laboratories
  • GenScript
  • Thermo Fisher Scientific, Inc.
  • Lonza
  • Catalent
  • Eurofins Scientific
  • Danaher
  • Merck KGaA
  • Revvity, Inc.
  • Sartorius AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.4 Billion
Compound Annual Growth Rate19.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cell & Gene Therapy Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Test Type (Bioavailability & Bioequivalence Studies), Product Type, Stage Of Development By Product Type, Indication, Region, and Segment Forecasts, 2024-2030 - Product Image

Cell & Gene Therapy Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Test Type (Bioavailability & Bioequivalence Studies), Product Type, Stage Of Development By Product Type, Indication, Region, and Segment Forecasts, 2024-2030

  • Report
  • 261 Pages
  • Global
From
Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 217 Pages
  • Global
From
Cell and Gene Therapy Third-Party Logistics Market Size, Share & Trends Analysis Report by Type (Clinical), Product (Cell Therapies, Gene Therapies), Temperature Range (Ambient Storage), Therapeutic Area, End-use, Region, with Growth Forecasts, 2025-2030 - Product Image

Cell and Gene Therapy Third-Party Logistics Market Size, Share & Trends Analysis Report by Type (Clinical), Product (Cell Therapies, Gene Therapies), Temperature Range (Ambient Storage), Therapeutic Area, End-use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030 - Product Image

Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.